Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

Advances in Immunotherapy & Resectable Non-Small Cell Lung CancerПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Clinical trials of neoadjuvant targeted therapy in resectable NSCLCПодробнее

Clinical Trial for Early-Stage Non-Small Cell Lung Cancer Following SurgeryПодробнее

Immunotherapy as combination and neoadjuvant therapies in NSCLCПодробнее

Current Status of Adjuvant Therapy for NSCLCПодробнее

Immunotherapy in Early Stage NSCLCПодробнее

Immunotherapy for Early-Stage Resectable NSCLC: Optimizing Multidisciplinary Management TodayПодробнее

Practical Application of Recent Clinical Data for Immunotherapy in NSCLCПодробнее

Early-Stage Resectable NSCLC: A Shifting Landscape With Targeted Therapies and ImmunotherapyПодробнее

Moving immunotherapy to earlier lines in NSCLCПодробнее

Clinical Trial for Stage IV Lung Cancer (NSCLC): BTCRC-LUN17-139Подробнее

In The Headlines: New Data on Targeted Systemic Treatment for Early-Stage Resectable NSCLCПодробнее

Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung CancerПодробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Using First-Line Immunotherapy in Stage 4 NSCLCПодробнее

8 in 8: Update on Immunotherapy for Resectable Lung CancerПодробнее

Immunotherapies in Lung Cancer | 2022 Evolution ConferenceПодробнее

IMpower010 supports adjuvant atezolizumab in early-stage NSCLC | Heather WakeleeПодробнее